

10 Literaturverzeichnis

- **A**lexander GM, Schwartzman RJ, Grothusen JR, et al. (1993): Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-Dopa treatment. *Brain Res* 625 (2): 276-82
- Arinami T, Gao M, Hamaguchi H, et al. (1997): A functional polymorphism in the promotor region of the dopamine D2 receptor gene is associated with schizophrenia. *Hum Mol Genet* 6: 577-82
- Armstrong M, Daly AK, Cholerton S (1992): Mutant debrisoquine hydroxylase genes in Parkinson's disease. *Lancet* 339: 1017-18

- **B**andmann (1995): Sequence of the superoxide dismutase 1 (SOD1) gene in familial Parkinson's disease. *J Neurosurg Psychiatry* 59 (1): 90-91
- Bedard PJ, Blanchet PJ, Calon F, et al. (1994): The paradox of dyskinesia and wearing off. A hypothesis based on observation in the MPTP monkey model of parkinsonism. *Mov Disord* 9 (Suppl 1): 153
- Birkmayer W, Hornykiewicz O (1961): Der L-Diphenylalanin (L-Dopa)-Effekt bei der Parkinson-Akinese. *Wien: Klin Wschr* 73: 787-88
- Birkmayer W, Danielczyk W, Neumayer E, et al. (1974): Nucleus ruber and L-Dopa-Psychosis: Biochemical post-mortem findings. *J Neural Transm* 35: 93-116
- Birkmayer W, Riederer P: *Die Parkinson-Krankheit: Biochemie, Klinik, Therapie*. 2. Aufl. Springer, Wien 1985

- **C**alon F, Grondin R, Morissette M, et al. (2000): Molecular basis of levodopa-induced dyskinesias. *Ann Neurol* 47 (4 Suppl 1): 70-78
- Catalano M, Nobile M, Novelli E, et al. (1993): Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. *Biol Psychiatry* 34 (7): 459-64

- Cedarbaum JM (1990): Pharmacokinetic and pharmacodynamic consideration in management of motor response fluctuations in Parkinson's disease. *Neurol Clin* 8 (1): 31-49
- Cortes R, Camps M, Gueye B, et al. (1989): Autoradiographic distribution of D1 and D2 sites in Parkinson's syndrome of different etiology. *Brain Res* 483: 30-38
- Crocq MA, Mant R, Asherson P, et al. (1992): Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. *J Med Genet* 29: 585-560
- Crocq MA, Buguet A, Bissler S, et al. (1996): *BaII* and *MspI* Polymorphisms of the Dopamine D3 Receptor gene in African Blacks and Caucasians. *Hum Hered* 46: 58-60
- Cummings JL (1991): Behavioral complications of drug treatment of Parkinson's disease. *J Am Geriatr Soc* 39: 708-16
- Cummings JL (1988): The dementias of Parkinson's disease: prevalence, characteristic, neurobiology and comparison with dementia of the Alzheimer Type. *Eur Neurol* 28 (Suppl 1): 15-23
- Cummings JL: Neuropsychiatric complications of drug treatment of Parkinson's disease. In: Huber SJ, Cummings JL (eds.): *Parkinson's Disease: Neurobehavioral aspects*. Oxford University Press, New York, NY 1992, S. 313-27

- Danielczyk W (1992): Mental disorders in Parkinson's disease. *J Neural Transm (Suppl* 38): 115-27
- De Michele G, Filla A, Marconi R, et al. (1995): A genetic study of Parkinson's disease. *J Neural Transmission* 45: 21-25
- Denny AP, Behari M (1999): Motor fluctuations in Parkinson's disease. *J Neuro Sci* 165: 8-23
- Dubois B, Ruberg M, Javoy-Agid F, et al. (1983): A subcorticocortical cholinergic system is affected in Parkinson's disease. *Brain research* 288: 213-218

- Ehringer H, Hornykiewicz O (1960): Verteilung von NA und Dopamin im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. *Klin Wschr* 38: 1236-39

- **F**actor SA, Molho ES, Podskalny GD, et al. (1995): Parkinson's disease: drug-induced psychiatric states. *Adv Neurol* 65: 115-38
- Feldon J, Weiner O (1992): From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. *J Psychiat Res* 26: 345-66
- Feuerstein C, Tanche M, Serre F, et al. (1977): Does O-Methyldopa play a role in levodopa-induced dyskinesias? *Acta Neurol Scand* 56: 79-82
- Fischer P, Danielczyk W, Simanyi M, et al. (1990): Dopaminergic psychosis in advanced Parkinson's disease. *Adv Neurol* 53: 391-97
- Fischer PA (1995): treatment strategies in Parkinson's disease after a quarter century experiences with L-Dopa therapy. *J Neural Transm (Suppl)* 46: 381-389
- Fischer PA und Friesling B: *Morbus Parkinson – neue Möglichkeiten mit Lisurid*. De Gruyter 1989
- Fuke S, Suo S, Takahashi N (2001): The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. *The Pharmacogenomics J* 1: 152-56

- **G**asser T (1996): Spielen genetische Faktoren in der Entstehung des idiopathischen Parkinsonsyndroms eine Rolle? *Psycho* 22: 48-53
- Gasser T, Wszolek ZK, Trofatter J, et al. (1994): Genetic linkage studies in autosomal parkinsonism: evaluation of seven candidate genes. *Ann Neurol* 36: 387-9663-70
- Gerlach M, Riederer P, Youdim MBH: Molecular mechanisms for neurodegeneration: Synergism between reactive oxygen species, calcium and exotoxic amino acid. In: *Parkinson's disease*, *Adv Neurol*. Battistin L, Scarlato G, Caraceni T, Ruggieri S (eds). Lippincott-Raven Philadelphia, New York, 1996
- Gibbs WRG, Lees AJ (1991): anatomy, pigmentation, ventral and dorsal subpopulation of the substantia nigra, and differential cell death in Parkinson's disease. *J Neurol Neurosurg Psychiat* 54: 388-96
- Gibbs WRG, Lees AJ (1988): The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiat* 51: 745-752
- Goetz CG, Burke PF, Leurgans S, et al. (2001): Genetic variations analysis in Parkinson's disease patients with and without hallucinations: a case-control study. *Arch Neurol* 58 (2): 209-13

- Goetz CG, Tanner CM, Klawans HL (1982): Pharmacology of hallucinations induced by long-term drug therapy. *Am J Psychiatry* 139: 494-47
- Golbe LI (1991): Young-onset Parkinson's disease: a clinical review. *Neurology* 41 (2): 168-73
- Graham JM, Grünewald RA, Sagar HJ (1997): Hallucinosi s in idiopathic Parkinson's disease. *J Neurol Neurosurg Psychiatr* 63: 434-40
- Grandy DK, Zhang Y, Civelli O (1993): PCR detection of the Taq1A RFLP at the DRD2 locus. *Hum Mol Gen* 2: 2197
- Griffon N, Crocq MA, Pilon C, et al. (1996): Dopamine D3 receptor gene: organization, transcript variants, and polymorphism associated with schizophrenia. *Am J Med Genet* 67 (1): 63-70

- **H**agell P, Widner H (1999): Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. *Mov Disord* 14: 448-55
- Hardie RJ (1989): Problems and unanswered questions concerning levodopa treatment in Parkinson's disease. *Acta Neurol* 126: 77-82
- Heinz A, Goldman D, Jones DW, et al. (2000): Genotype influences in vivo dopamine transporter availability in human striatum. *Neuropsychopharmacology* 22 (2): 133-39
- Hely MA, Fung VS, Morris JG (2000): Treatment of Parkinson's Disease. *J Clin Neurosci* 7 (6): 484-94
- Higuchi S, Muramatsu T, Arai H, et al. (1995): Polymorphisms of dopamine receptor and transport genes and Parkinson's disease. *J Neural Transm Park Dis Dement Sect.*10 (2-3): 107-13
- Hippus H (1989): The history of clozapine. *Psychopharmacology* 99: 3-5
- Hoehn MM, Yahr MD (1967): Parkinsonism: onset, progression and mortality. *Neurology* 17 (5): 427-42
- Hong CJ, Chiu HJ, Chang YS et al. (1998): Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. *Biol Psychiatry* 43 (6): 432-5
- Horn AS (1990): Dopamine uptake: a review of progress in the last decade. *Prog Neurobiol* 34 (5): 387-400

- Hughes* AJ, Colosimo C, Kleedorfer B, et al. (1992): The dopaminergic response in multiple system atrophy. *J Neuro Neurosurg Psychiat* 55: 1009-13
- Hughes** AJ, Daniel SE, Kilford L (1992): Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 55: 181-84
- Hughes AJ, Frabkel JP, Kempster PA (1993): Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. *J Neurol Neurosurg and Psych* 57: 430-34

- **J**acobsen LK, Staley JK, Zoghbi SS, et al. (2000): Prediction of dopamine transporter binding availability by genotype: a preliminary report. *Am J Psychiatry* 157 (10): 1700-03
- Jörg J (1988): Therapie im Frühstadium des Parkinson-Syndroms, *Nervenheilkunde* 7: 1-5

- **K**ippervasser S, Inzelberg R, Korczyn AD (1996): Auditory hallucinations in Parkinson's disease. *Mov Disord* 11 (Suppl 1): 194
- Kondo K, Kurland LT, Schull WJ (1973): Parkinson's disease, genetic analysis and evidence of multifactorial etiology. *Mayo Clin Proc* 48: 465-75
- Kostic V, Przedborski S, Flaster E, et al. (1991): Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. *Neurology* 41 (2): 202-05
- Kronenberg MF, Menzal HJ, Ebersbach G (1999): Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. *Eur J Hum Genet* 7: 397-400
- Kupsch A, Sautter J, Schwarz J (1996): 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. *Brain Res* 741 (1-2): 185-96
- Kurth JH, Kurth MC, Poduslo SE (1993): Association of a monoamine oxidase B allele with Parkinson's disease. *Neurology* 33: 368-72

- **L**ang* AE, Lozano AM (1998): Parkinson's disease. First of two parts. *N Engl J Med* 339 (15): 1044-52

- Lang** AE, Lozano AM (1998): Parkinson's disease. Second of two parts. *N Engl J Med* 339 (16): 1130-43
- Lannfeldt L, Sokoloff P, Martres MP, et al. (1992): Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. *Psychiatric Genetics* 2: 249-56
- Le Couteur DG, Leighton PW, et al. (1997): Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. *Mov Dis* 12: 760-763
- Lee T, Seeman P, Rajput A, et al. (1978): Receptor basis for dopaminergic supersensitivity in Parkinson's disease. *Nature* 273: 59-61
- Lees AJ (1993): Dopamine agonists in Parkinson's disease: a look at apomorphine. *Fundam Clin Pharmacol* 7: 121-28
- Leighton PW, Le Couteur DG, et al. (1997): The dopamine transporter gene and Parkinson's disease in a Chinese population. *Neurology* 49: 1577-79
- Li T, Yang L, Wiese C, et al. (1994): No association between alleles or genotypes at the dopamine transporter gene and schizophrenia. *Psychol Res* 52: 17-23
- Lin JJ, Yueh KC, Chang DC, et al. (2003): The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not for female patients. *J Neurol Science*, 209 (1-2): 87-92
- Lin C, Liu H, Tsai S, et al. (2002): Association study for Parkinson's Disease and a dopamine transporter gene polymorphism (1215A/G). *Eur Neurol* 48: 207-09
- Ludin HP (1998): Morbus Parkinson: neue Behandlungsmöglichkeiten, *Pharmakritik Jahrgang 19, Nr.17. Arbeitsgruppe der Therapiekommission der Schweizerischen Neurologischen Gesellschaft (SNG). Schweiz Ärztes* 79: 425-30

- Makoff AJ, Graham JM, Arranz MJ, et al. (2000): Association study with drug-induced hallucination in patients with idiopathic Parkinson's disease. *Pharmacogenetics* 10: 43-48
- Marder K, Tang MX, Mejia H, et al. (1996): Risk of Parkinson's disease among first-degree relatives: A community based study. *Neurology* 47: 155-60
- Martilla R, Rinne U (1976): Dementia in Parkinson's disease. *Acta Neurol Scand* 54: 431-41

- Mayeux R: Depression und dementia in Parkinson's disease. In: Marsden CD, Fahn S (Hrsg): Movement disorders, Butterworth, London 1981, S. 75-95
- Martinez D, Gelernter J, Abi-Dargham A, et al. (2001): The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. *Neuropsychopharmacology* 24 (5): 553-60
- Meco G, Bonifati V, Cusimano G, et al. (1990): Hallucinations in Parkinson's disease: neuropsychological study. *Ital J Neurol Sci* 11: 373-79
- Mena MA, Muradas V, Bazan E, et al. (1986): Pharmacokinetics of L-Dopa in patients with Parkinson's disease. *Adv Neurol* 45: 481-86
- Mercier G, Turpin JC, Lucotte G (1999): Variable number tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association. *J Neurol* 246: 45-47
- Michelhaugh GM, Fiskerstrand C, Lovejoy E, et al. (2001): The dopamine transporter gene (SLC6A3) variable tandem repeats domain enhances transcription in dopamine neurons. *J Neurochem* 79 (5): 1033-38
- Miller GM, Madras BK (2002): Polymorphisms in the 3'-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. *Mol Psych* 7: 44-55
- Missale C, Nash RS, Robinson SW, et al. (1998): Dopamine receptors: From structure to function. *Physiological reviews* Vol. 78, 1 : 189-216
- Morino H, Kawarai T, Izumi Y, et al. (2000): A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson's disease. *Ann Neurol* 47: 528-31
- Moscovitz C, Moses H, Klawans HL (1978): Levodopa-induced psychosis: a kindling phenomenon. *Am J Psychiatry* 135: 6669-75
- Murata M, Kanzawa I (1997): Effects of chronic Levodopa therapy on Dopa pharmacokinetics. *Eur Neurol* 38 (Suppl 2): 50-55
- Nanko S, Ueki A, Hattori M, et al. (1994): No allelic association between Parkinson's disease and Dopamine D2, D3, and D4 receptor gene polymorphisms. *Am J Med Genet* 54 (4): 361-64

- Nanko S, Hattori M (1993): Dopamine D3 and D4 receptor gene polymorphisms and Parkinson's disease. *Lancet* Vol. 342: 250
- Nausieda PA, Weiner WJ, Kaplan LR, et al. (1982): Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. *Clin Neuropharmacol* 5: 183-94
- Neundörfer B: Die Parkinsonsche Krankheit. Ein Lehrbuch für Patienten und ihre Angehörigen. Gustav Fischer Verlag, Stuttgart-New York 1990
- Nishimura M, Kaji R, Ohta M, et al. (2002) . Association between dopamine transporter gene polymorphism and susceptibility to Parkinson's disease in Japan. *Mov Disord* 17 (4): 831-32
- Nöthen M, Cichon S, Hemmer S, et al. (1994): Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. *Hum Mol Genet* 3 (12): 2207-12

- **O**liveri RL, Annesi G, Zappia MD, et al. (1999): Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. *Neurology* 53 (2 of 2): 1425-30

- **P**antelatos A, Fornadi F (1993): Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age of onset. *Adv Neurol* 60: 690-97
- Papa SM, Chase TN (1996): Levodopa-induced dyskinesia improved by a glutamate agonist in parkinsonian monkeys. *Ann Neurol* 39: 574-578
- Parkinson, J: *Essay on the Shaking Palsy*. Whittingham and Rowland, London 1817
- Persico AM, Wang ZW, Black DW, et al. (1995): Exclusion of close linkage of the dopamine transporter gene with schizophrenia spectrum disorders. *Am J Psychiatry* 152 (1): 134-36
- Piccini P, Weeks RA, Burn DJ, et al. (1996): PET studies on opioid receptor binding in Parkinson's disease patients with and without levodopa-induced dyskinesias. *Neurology* 46 (Suppl 1): A454
- Planté-Bordeneuve V, Taussig D, Thomas F, et al. (1997): Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease: evidence for association of a DRD2 allele. *Neurology* 48: 1589-93

- Poewe WH (1994): Clinical aspects of motor fluctuations in Parkinson's disease. *Neurology* 44 (7 Suppl 6): 6-9
- Polymeropoulos MH, Lavedan C, Leroy E, et al. (1997): Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* 276: 2045-47

- **Reef HE**: Prevalence of Parkinson's disease in a multiracial community. In: Hartog Jager, WA, Bruyn GW (eds), 11th World Congress of Neuro. Excerpta Medica Amsterdam, 1977
- Ricketts MH, Hamer HM, Manowitz P, et al. (1998): Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease. *Clin Genet* 54 (1): 33-38
- Riederer P: Biochemie dopaminerger Symptome. In: Fischer PA, Friesling B (Hrsg.): *Morbus Parkinson – neue Möglichkeiten mit Lisurid*. De Gruyter 1989, S. 12
- Riederer G, Umek H (Hrsg.): *L-Dopa-Substitution der Parkinson Krankheit. Geschichte-Gegenwart-Zukunft*. SpringerVerlag, Wien-NY 1985
- Riess O, Krüger R, Schöls L, et al. (1999): Zur Genetik und Pathogenese des Morbus Parkinson. *Deutsches Ärzteblatt* 96, Heft 43: C-2007-13
- Rietschel M, Naber D, Oberländer H, et al. (1996): Efficiency and side-effects of Clozapine: Testing for association with allelic variation in the dopamine D4 receptor gene. *Neuropsychopharmacology*: Vol 15 (5): 491-96
- Rinne* JO (1991): Nigral degeneration in Parkinson's disease in relation to clinical features. *Acta Neurol. Scand.* 84 (Suppl 136): 87-90
- Rinne** JO, Laihinén A, Lonnberg P, et al. (1991): A post-mortem study on striatal dopamine receptors in Parkinson's disease. *Brain Res* 556: 117-22
- Rodriguez M, Lera G, Vaamonde J, et al. (1994): Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. *J Neurol Neurosurg Psychiatr* 57: 562-66
- Rondot P, de Recondo J, Coignet A, et al. (1984): Mental disorders in Parkinson's disease after treatment with L-Dopa. *Adv Neurol* 40: 259-69

- **Sanchez-Ramos JR, Ortoll R, Paulson GW** (1996): Visual hallucinations associated with Parkinson's disease. *Arch Neurol* 53: 1265-68

- Sano A, Kondoh K, Kakimoto Y, et al. (1993): A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. *Hum Genet* 91 (4): 405-06
- Schapira AH (2006): Etiology of Parkinson's disease. *Neurology* 66 (10 Suppl. 4): 10-23
- Schneider P-A, Kessler II, Diamond EL (1971): Epidemiology studies of Parkinson's disease. *Am J Epidemiol*: 16-25
- Schrag A, Ben-Shlomo Y, Brown R, et al. (1998): Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. *Mov Disord* 13: 885-94
- Seeman P, Van Toel HH (1993): Dopamine D4 receptors bind inactive (+)-apomorphines, suggesting neuroleptic role. Sulpiride not stereoselective. *Eur J Pharmacol* 233: 173-74
- Shaikh S, Collier D, Sham P, et al. (1996): Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schiziphrenia. *Hum Genet* 97: 714-19
- Shaw KM, Lees AJ, Stern GM (1980): The impact of treatment with levodopa on Parkinson's disease. *Q J Med* 49 (195): 283-93
- Sokoloff P, Giros B, Martres MP, et al. (1990): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. *Nature* 347: 146-51

- **Tan** EK, Khajavi M, Thornby JI (2000): Variability and validity of polymorphism association studies in Parkinson's disease. *Neurology* 55 (4): 533-38
- Tanner CM, Chen B, Wang W, et al. (1989): Environmental factors and Parkinson's disease: a case-control study in China. *Neurology* 39: 660-664
- Taylor AE, Saint-Cyr JA, Lang AE (1986): Frontal lobe dysfunction in Parkinson's disease. The cortical focus on neostriatal outflow. *Brain* 109: 845-883
- Tertiakoff, C: Contribution a l'etude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives a la pathologie des troubles musculaires et de la maladie de Parkinson. Jouve, Paris 1919
- Tetrud JW, Langston JW (1989): The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. *Science* 245: 519-522
- The Parkinson Study Group (1989): Effect of deprenyl on the progression of disability in early Parkinson's disease. *N Engl J Med* 321: 1364-47
- Tipton KF, Singer TP (1993): Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. *J Neurochem* 61 (4): 1191-206

- Turjanski N, Lees AJ, Brooks DJ (1997): In vivo studies on striatal dopamine D1 and D2 site binding in L-Dopa-treated Parkinson's disease patients with and without dyskinesias. *Neurologie* 49: 717-23

- Uhl GR, Kitayama S (1993): A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis. *Adv Neurol* 60: 321-24

- Vandenberg DJ, Persico AM, Hawkins AL, et al. (1992): Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. *Genomics* 14: 1104-06
- Van Praag HM: Serotonin and affective psychopathology in Parkinson's disease. A psychobiological hypothesis with therapeutic consequences. In: Wolters EC, Scheltens P (eds.): *Mental dysfunction in Parkinson's disease*. Dordrecht, The Netherlands: ICG Publications 1994, S. 335-48
- Van Tol HHM, Caren MW, Guan HC, et al. (1992): Multiple dopamine D4 receptor variants in the human population. *Nature* 358: 149-152
- Verhagen M, Del Dotto P, van den Munckhof P, et al. (1998): Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. *Neurology* 50 (5): 1323-26
- Vieregge P, Klein C, Pulkowski U, et al. (1996): Visual hallucinations in Parkinson's disease: a controlled study. *Mov Disord* 11 (Suppl 1): 158

- Wan DC, Law LK, Cheung WT (1999): Lack of allelic association of dopamine D4 receptor gene polymorphisms with Parkinson's disease in Chinese population. *Mov Disord* 14: 225-29
- Wang J, Liu ZL, Chen B (2001): Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in Parkinson's disease. *Neurology* 56: 1757-59
- Wang J, Zhao C, Chen B (2004): Polymorphisms of dopamine receptor genes and hallucinations in Parkinson's disease. *Neuroscience Letter* 355: 193-96
- William J, Weiner MD (1999): The initial treatment of Parkinson's disease should begin with levodopa. *Mov Disord* 14 (5): 716-24
- Wolters EC, Kuiper MA, Zwaan WA, et al.: Dopaminomimetic psychosis: therapeutic strategies. In: Wolters EC, Scheltens P (eds.): *Mental dysfunction in Parkinson's disease*. Dordrecht, The Netherlands: ICG Publications 1994, S. 285-95

- Wolters EC, Jansen ENH, Tuynman-Qua HG, et al. (1996): Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. *Neurology* 47: 1085-87
- Wolters E (1999): Dopaminomimetic psychosis in Parkinson's disease patients: Diagnosis and treatment. *Neurology* 52 (Suppl. 3): 10-13

- **Z**appia M, Montesanti R, Colao R, et al. (1997): Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. *Mov Disorders* 12 (1): 103-06
- Zhang L, Shao M, Dong X (2001): Association between dopamine transporter gene polymorphism and Parkinson's disease. *Zhonghua Yi Xue Yi Chuan Za Zhi* 18 (6): 431-34
- Zoldan J, Friedberg G, Livneh M, et al. (1995): Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5HT₃ receptor agonist. *Neurology* 45: 1305-8